Adiponectin relates to smooth muscle function and folate in obese children

Alexia Sophie Peña1, Damien P Belobrajdic, Esko Wiltshire

  • 1Department of Endocrinology and Diabetes, Women's and Children's Hospital, North Adelaide, South Australia, Australia. alexia.pena@adelaide.edu.au

Insights

Obese children have lower adiponectin levels, impacting vascular function. Folic acid supplementation did not improve adiponectin in obese children, despite improving folate status.

Area of Science:

  • Pediatric endocrinology
  • Cardiovascular health
  • Nutritional science

Background:

  • Adiponectin, an adipocyte-specific protein, influences nitric oxide production and may link visceral obesity to vascular dysfunction.
  • Lower adiponectin levels are observed in obese children, but its association with vascular function in this demographic remains unclear.

Purpose of the Study:

  • To investigate the relationship between adiponectin levels and vascular function in both obese and healthy children.

Main Methods:

  • A cross-sectional study involving 49 obese and 33 non-obese children (mean age 13.4 years).
  • Measurements included adiponectin, flow-mediated dilation (FMD), glyceryl trinitrate-induced dilation (GTN), serum folate, red cell folate (RCF), homocysteine, lipids, glucose, and insulin.
  • A randomized folate intervention trial was analyzed to assess the effect of folic acid supplementation on adiponectin in obese children.

Main Results:

  • Obese children exhibited significantly lower adiponectin, FMD, and GTN compared to non-obese children.
  • In obese children, adiponectin correlated with GTN, RCF, and LDL cholesterol, and was influenced by female gender.
  • Folic acid supplementation increased serum folate and RCF while decreasing homocysteine, but did not alter adiponectin levels in obese children.

Conclusions:

  • Obese children present with reduced adiponectin levels, associated with impaired smooth muscle function and lower folate status.
  • Despite a clear link between adiponectin and folate status, folic acid supplementation does not enhance adiponectin levels in obese children.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.